Goldman Sachs maintained a Sell rating on Teva Pharma (NYSE: TEVA) with a price target of $40.00. Analyst Jami Rubin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE